Randox Licenses sPLA2 CVD Risk Test from Aterovax

Product News   May 02, 2013

 
Randox Licenses sPLA2 CVD Risk Test from Aterovax
 
 
FURTHER INFORMATION
 
 
 

Related Product News


Precision Medicine Meets Single-Cell DNA Analysis With Mission Bio

Product News

Company closes Series A and launches Tapestri™ to accelerate the discovery, development and delivery of precision medicine.

READ MORE


Like what you just read? You can find similar content on the communities below.

Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE